Immunogenicity against SARS-CoV-2 variants of concern of ChAdOx1 nCoV-19 vaccine, Sinovac's CoronaVac vaccine, heterologous vaccines and the third boosting vaccine in the elderly and COPD patients

Conditions

COPD, post SAR-COV-2 (COVID-19 virus) infection Healthy elderly COPD, post SAR-COV-2 (COVID-19 virus) infection Healthy elderly, COVID-19, immunology

Warawut Chaiwong, Nuchjira Takheaw, Witida Laopajon, Chote Nisoong, Supansa Pata et al. (17 authors)

Vaccine2025-06-041 citations

10.1016/j.vaccine.2025.127330

Immune Responses Against SARS-CoV-2 in Previously SARS-CoV-2-Infected Individuals after Receiving a Single Dose of CoronaVac or ChAdOx-1 Vaccine

Witida Laopajon, Athavudh Deesomchok, Warawut Chaiwong, Nuchjira Takheaw, Supansa Pata et al. (18 authors)

Infection and Chemotherapy2025-01-01

10.3947/ic.2024.0145

Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.

Chaiwong W, Takheaw N, Pata S, Laopajon W, Duangjit P, Inchai J, Pothirat C, Bumroongkit C, Deesomchok A, Theerakittikul T, Limsukon A, Tajarernmuang P, Niyatiwatchanchai N, Trongtrakul K, Chuensirikulchai K, Cheyasawan P, Liwsrisakun C, Kasinrerk W.

2023-08-182 citations

10.1016/j.vaccine.2023.08.034

Interventions

COPD who received standard 2-dose of ChAdOx-1 vaccine ,COPD who received heterologous (CoronaVac/ChAdOx-1) vaccine regimen,Healthy elderly who received standard 2-dose of ChAdOx-1 vaccine ,Healthy eld

Basic Science,Basic Science,Basic Science,Basic Science,Basic Science,Basic Science,Basic Science,Basic Science

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Elderly (age >60 years) subjects and spirometry-confirmed COPD patients at any age 2. Receiving any 3 national authorized COVID-19 vaccine regimens (CoronaVac/ChAdOx-1, 2-dose ChAdOx-1 vaccine and 2-dose CoronaVac vaccine) 3. Boosting with either virus-vectored or mRNA vaccine following standard 2-dose of CoronaVac vaccine

Exclusion criteria

Exclusion criteria: 1. No history of previously diagnosed COVID-19 except positive control group 2. No history of COPD exacerbation within previous 3 months 3. High-risk of active infection within 14 days before enrollment e.g. close contact with index cases or visiting/ living in outbreak area 4. History of receiving other vaccines against SARS-CoV-2 5. Participating in other vaccine clinical trial 6. History of receiving blood products, blood components, or immunoglobulin within the past 90 days 7. History of receiving attenuated live vaccine in the past 28 days 8. History of receiving inactivated or subunit vaccines in the past 14 days 9. History of allergy to any vaccine component 10. Underlying uncontrolled diabetes, uncontrolled cardiovascular disease, uncontrolled pulmonary disease, end-stage renal disease requiring dialysis, cirrhosis, immunocompromised host or receiving immunosuppressive agents 11. Unable to make the decision and sign consent by themselves

Design outcomes

Primary

Measure	Time frame
Neutralizing antibody Baseline and wk 4, 12, 24, 36, 48 post the last dose RU/ml	—

Secondary

Measure	Time frame
Cell-mediated immunity (CMI) Baseline and wk 4, 12, 24, 36, 48 post the last dose percent of positive cell,Cell-mediated immunity (CMI) Baseline and wk 4, 12, 24, 36, 48 post the last dose Mean fluorescent intensity	—

Countries

Thailand

Contacts

Public ContactChaicharn Pothirat

Chiang Mai University

chaicharn.p@cmu.ac.th66815309950

Outcome results

None listed

Immunogenicity against SARS-CoV-2 variants of concern of ChAdOx1 nCoV-19 vaccine, Sinovac&#039;s CoronaVac vaccine, heterologous vaccines and the third boosting vaccine in the elderly and COPD patients